CELLMED (셀메드)

Cellmed Orthocellular Medicine and Pharmaceutical Association (셀메드 세포교정의약학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Majoon Idraare Haiz in Polycystic Ovarian Syndrome - A pilot study

  • Received : 2021.12.15
  • Accepted : 2022.02.24
  • Published : 2022.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Background & Objectives: Polycystic ovarian syndrome (PCOS) is one of the commonest endocrine abnormality in women of reproductive age affecting from 4% - 21% of the reproductive women and is characterized by chronic anovulation and hyperandrogenism. The aim of the study was to evaluate the effect of majoon idraare haiz in menstrual regulation and morphological changes in ovaries in poly cystic ovarian syndrome. Methods: A Pilot study was carried out in the department of Ilmul qabalat wa amraze niswan, National institute of unani medicine, hospital, Bengaluru. Fifteen Patients of PCOS aged 18-35 diagnosed using Rotterdam criteria were included in the study. Patients with insulin sensitizing treatment within 3 months, hormonal treatment and those with h/o diabetes mellitus, hypertension, pregnant and lactating women were excluded.Majoon idraare haiz was administered orally at a dose of 10 g with 20 ml arqbed mushk once daily from fifth day of cycle for 21 days for three consecutive cycles. Primary outcome measure was menstrual regularity while changes in USG pelvis(normal ovarian morphology) was considered as secondary outcome measure. In addition, duration of flow and changes in basal metabolic index (BMI), modified Ferriman Gallwey (mFG) score, acanthosis nigricanswere observed. Data were analyzed using, ANOVA, paired student 't' test, fisher exact test. Results: Changes in duration of cycle, duration and amount of flow was achieved in 93.3% patients with p<0.0001 and 46.6% patients showed normal findings on pelvic ultrasonography with p=0.006. In addition, significant changes were also observed in BMI, hirsutism and acanthosis nigricans with p value of 0.0001, p=0.003 and p=0.009 respectively Conclusion: Majoonidraare haiz can be used as an effective alternative in management of PCOS patients. It has significant effect on menstrual regulation and changes in polycystic ovarian morphology to normal.

Keywords

References

  1. Al-Asmari AK, Athar MT, & Kadasah SG. An updated phytopharmacological review on medicinal plant of Arab region: Apium graveolens linn. Pharmacognosy reviews, 2017;11(21);13. https://doi.org/10.4103/phrev.phrev_35_16
  2. Al-Snafi AE. The pharmacological importance of Anethum graveolens-A review. International Journal of Pharmacy and Pharmaceutical Sciences, 2014;6(4);11-13.
  3. Amrohawi HJ. Qarabadeen Jalali. CCRIUM, 2004.
  4. Anonymous. Standardization of Single Drugs of Unani Medicine. CCRUM, 1992.
  5. Arentz S, Smith CA, Abbott J, Fahey P, Cheema BS, &Bensoussan A. Combined lifestyle and herbal medicine in overweight women with polycystic ovary syndrome (PCOS): a randomized controlled trial. Phytotherapy research, 2017;31(9);1330-1340. https://doi.org/10.1002/ptr.5858
  6. Baghdadi. Kitab-al-Mukhtarat Fil Tibb. CCRUM, 2007.
  7. Balakrishnan A. Therapeutic uses of peppermint-a review. Journal of pharmaceutical sciences and research, 2015;7(7); 474.
  8. Barbosa G, de Sa, LBPC, Rocha, DRTW & Arbex AK. Polycystic ovary syndrome (PCOS) and fertility. Open Journal of Endocrine and Metabolic Diseases, 2016;6(1);58-65. https://doi.org/10.4236/ojemd.2016.61008
  9. Bashtian MH, Emami SA, Mousavifar N, Esmaily HA, Mahmoudi M & Poor AHM. Evaluation of fenugreek (Trigonella foenum-graceum L.), effects seeds extract on insulin resistance in women with polycystic ovarian syndrome. Iranian journal of pharmaceutical research: IJPR, 2013;12(2);475.
  10. Bhat SA, Raza A, Shahabuddin M.Clinical Study of Polycystic Ovarian Syndrome with a Unani Formulation: A randomized single - blind placebo controlled study. World Journal of Pharmaceutical Sciences,2015;3(3);177.
  11. Bieber EJ, Sanfilippo JS, Horowitz I. Clinical Gynaecology. (PA; Elsevier), 2006
  12. Brahmi F, Khodir M, Mohamed C & Pierre D. Chemical composition and biological activities of Mentha species. Aromatic and medicinal plants-Back to nature, 2017;10;47-79.
  13. Choudhary A, Jain S & Chaudhari P. Prevalence and symptomatology of polycystic ovarian syndrome in Indian women: is there a rising incidence?. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2017;6(11); 4971-4976. https://doi.org/10.18203/2320-1770.ijrcog20175010
  14. Farzana F, Sulaiman A, Ruckmani A, Vijayalakshmi K, Karunya Lakshmi G & Shri Ranjini S. Effects of flax seeds supplementation in polycystic ovarian syndrome. Int J Pharm Sci Rev Res, 2015;31(1);113-119.
  15. Firdose KF, Anjum A. An overview of Mentha pulegium - A Versatile Unani Drug. Journal of Research in Indian Medicine. 2020;15(2);5.
  16. Firdose KF, Anjum A. A Comprehensive Review of Juniperus communis with Special Reference to Gynecology and Unani Medicine. International Journal of Innovative Science and Research Technology. 2020;5(10);118.
  17. Firdose KF & Shameem I. An approach to the management of poly cystic ovarian disease in Unani system of medicine: A review. Int j appl res, 2016;2(6);585-90.
  18. Gainder S & Sharma B. Update on management of polycystic ovarian syndrome for dermatologists. Indian dermatology online journal, 2019;10(2);97. https://doi.org/10.4103/idoj.IDOJ_249_17
  19. Hoffman BL, Schorge JO, Bradshaw KD, Halvorson LM, Schaffer JI & Corton MM. Williams gynecology. (NY; McGraw-Hill Education), 2016
  20. Iqbal A, Jan A, Quraishi HA, Raheem A. Concept and Management of Polycystic Ovarian Syndrome in Greeco Arabian Medicine: A Review Study. 2018;7(14);487-502.
  21. Kabiruddin. Makhzan-ul-Mufradat.Idarae Kitab al-Shifa, 2007
  22. Kamboj MK & Bonny AE. Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies. Translational pediatrics, 2017;6(4);248. https://doi.org/10.21037/tp.2017.09.11
  23. Kashani L& AkhondzadehS. Herbal medicine in the treatment of polycystic ovary syndrome. JMed Plants, 2016;15(59);1-5.
  24. Khan AA & Begum W. Efficacy of Darchini in the management of polycystic ovarian syndrome: a randomized clinical study. Journal of Herbal Medicine, 2019;15;100249. https://doi.org/10.1016/j.hermed.2018.11.005
  25. Khan A, Karim N, Ainuddin JA& Fahim MF. Polycystic Ovarian Syndrome: Correlation between clinical hyperandrogenism, anthropometric, metabolic and endocrine parameters. Pakistan Journal of Medical Sciences, 2019;35(5);1227.
  26. Khare CP. Indian Medicinal Plants, An illustrated Dictionary. Springer India (P) Ltd, 2007.
  27. Khatoon R & Shameem I. Effect of Muqil, Murmakki, Abhal in Polycystic Ovarian Disease associated Secondary Amenorrhea: An Observational study.IOSRJDMS, 2017;16(10);07-15.
  28. Khatoon R, Aslam M& Chaudhary SS. Ethnobotany and unani perspective of Tukhme Soya (Anethum sowa Roxb.). Journal of Drug Delivery and Therapeutics, 2019;9(3);537-542.
  29. Khomami MB, Tehrani FR, Hashemi S, Farahmand M & Azizi F. Of PCOS symptoms, hirsutism has the most significant impact on the quality of life of Iranian women. PLoS One, 2015;10(4);e0123608. https://doi.org/10.1371/journal.pone.0123608
  30. Kooti W, Ali-Akbari S, Asadi-Samani M, Ghadery H & Ashtary-Larky D. A review on medicinal plant of Apium graveolens. Future Natural Products, 2015;1(1);48-59.
  31. Kumar S, Kumari R & Mishra S. Pharmacological properties and their medicinal uses of Cinnamomum: A review. Journal of Pharmacy and Pharmacology, 2019;71(12);1735-1761. https://doi.org/10.1111/jphp.13173
  32. Lai L, Flower A, Prescott P, Wing T, Moore M& Lewith G. Standardized versus individualized multiherb Chinese herbal medicine for oligomenorrhoea and amenorrhoea in polycystic ovary syndrome: a randomized feasibility and pilot study in the UK. BMJ open, 2017;7(2);e011709. https://doi.org/10.1136/bmjopen-2016-011709
  33. Michl J, Bello O, Kite GC, Simmonds MS & Heinrich M. Medicinally used Asarum species: high-resolution LC-MS analysis of aristolochic acid analogs and in vitro toxicity screening in HK-2 cells. Frontiers in pharmacology, 2017;8;215. https://doi.org/10.3389/fphar.2017.00215
  34. Naeimi SA, Tansaz M, Sohrabvand F, Hajimehdipoor H, Nabimeybodi R, Saber S& Rohani, M. Assessing the effect of processed nigella sativa on oligomenorrhea and amenorrhea in patients with polycystic ovarian syndrome: a pilot study. International Journal Of Pharmaceutical Sciences And Research, 2018;9(11);4716-4722.
  35. Ndefo UA, Eaton A& Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. Pharmacy and therapeutics, 2013;38(6);336.
  36. Pal A, Modak R. Practical Manual of Gynaecology. (New Delhi; Jaypee Brothers Medical Publishers (P) Ltd), 2017.
  37. Purnell JQ. Definitions, classification, and epidemiology of obesity. Endotext. MDText.com, Inc, 2018.
  38. Saman A, Suboohi M, Naaz SA& Kazmi QA. Clinical evaluation of mizaj (temperament) in the patients of polycystic ovarian disease. International Ayurvedic Medical Journal (IAMJ), 2015;3(11);2173-2176.
  39. Shayan A, Masoumi SZ, Shobeiri F, Tohidi S& Khalili A. Comparing the effects of agnugol and metformin on oligomenorrhea in patients with polycystic ovary syndrome: A randomized clinical trial. Journal of clinical and diagnostic research: JCDR, 2016;10(12);QC13.
  40. Sowmya D & Anitha S. Clinical study of polycystic ovarian syndrome (PCOS) in tertiary care centre. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 2017;6(8);3247-3252. https://doi.org/10.18203/2320-1770.ijrcog20173144
  41. Zubair Z. Effect of Sharbat Afsantin in Poly Cystic Ovarian Disease - An open observational study: (Unpublished master's thesis). Rajiv Gandhi University of health sciences, Bengaluru, Karnataka, India, 2020.